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Abstract Pulmonary embolism (PE) can only be diagnosed
with imaging techniques, which in practice is performed
using ventilation/perfusion scintigraphy (V/PSCAN) or
multidetector computed tomography of the pulmonary
arteries (MDCT). The epidemiology, natural history, patho-
physiology and clinical presentation of PE are briefly
reviewed. The primary objective of Part 1 of the Task
Group’s report was to develop a methodological approach to
and interpretation criteria for PE. The basic principle for the
diagnosis of PE based upon V/PSCAN is to recognize lung
segments or subsegments without perfusion but preserved
ventilation, i.e. mismatch. Ventilation studies are in general
performed after inhalation of Krypton or technetium-labelled
aerosol of diethylene triamine pentaacetic acid (DTPA) or
Technegas. Perfusion studies are performed after intravenous
injection of macroaggregated human albumin. Radiation
exposure using documented isotope doses is 1.2–2 mSv.
Planar and tomographic techniques (V/PPLANAR and
V/PSPECT) are analysed. V/PSPECT has higher sensitivity
and specificity than V/PPLANAR. The interpretation of either
V/PPLANAR or V/PSPECT should follow holistic principles
rather than obsolete probabilistic rules. PE should be
reported when mismatch of more than one subsegment is
found. For the diagnosis of chronic PE, V/PSCAN is of value.
The additional diagnostic yield from V/PSCAN includes
chronic obstructive lung disease (COPD), heart failure and
pneumonia. Pitfalls in V/PSCAN interpretation are consid-
ered. V/PSPECT is strongly preferred to V/PPLANAR as the
former permits the accurate diagnosis of PE even in the
presence of comorbid diseases such as COPD and pneumo-
nia. Technegas is preferred to DTPA in patients with COPD.
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Abbreviations
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MDCT Multidetector computed tomography
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Introduction
PE is an important and treatable illness caused by migration
of thrombus to the pulmonary circulation commonly from
the veins of the lower extremities. Untreated, PE can cause
death [1] or lead to chronic thromboembolic pulmonary
hypertension [2]. Appropriate treatment can prevent recur-
rence of PE and facilitate resolution of existing clot, so
aiding recovery. However, treatments, which include
heparin, oral anticoagulants and thrombolytic agents, have
well-documented side effects. Therefore it is imperative that
early diagnosis of PE is made and that treatment is
instituted when appropriate.
While there are nonthrombotic causes of PE such as
septic, fat, amniotic fluid, and air emboli, the term PE in
this article is used to refer to thrombotic emboli. This is the
area where radionuclide lung scanning has been most
studied. This article explores the role of V/PSCAN and its
utility in the accurate diagnosis of PE due to thrombotic
disease. Moreover, the potential role of V/PSPECT for the
diagnosis of other cardiopulmonary diseases is presented as
well as its suitability for follow-up and research.
Epidemiology
The incidence of PE is notoriously difficult to establish due
to inaccuracies in hospital discharge records, but is
estimated to be in the region of 100 cases per 100,000
person years [3]. This estimate appears to be stable over
time since the incidence was the same in the 1980s as in the
1990s in the US [4]. In Malmö, Sweden, the prevalence of
PE at autopsy has been found to be 18% [5]. In 13% of
autopsies, PE was considered to be the main or contributory
cause of death. In the absence of risk factors, PE is rare in
children under 15 years of age (<5 per 100,000). It
increases dramatically after the age of 60 years [3]. The
incidence of VTE is similar in males and females. Risk
factors associated with the development of VTE are well
documented [6] and include inherited and acquired factors.
Amongst the acquired factors, underlying malignancy and
recent immobilization or surgery are the most important and
well-known ones. A more recently recognized risk factor is
long-distance flights, even in healthy individuals [7].
Natural history of PE
Early studies documented the natural history of VTE.
Using fibrinogen uptake, Kakkar et al. found that DVT
developed in 30% of 132 patients undergoing surgery
without prophylaxis [8]. DVT developed in the calf veins
in the majority, and propagated to the proximal leg veins in
13%. PE developed in 44% of patients with proximal
DVT. Further evidence that DVT and PE are distinct
manifestations of the same disease process, referred to as
VTE, comes from the observation that in the majority of
patients with PE, DVT can be detected using sensitive
methods. In patients with proven leg vein DVT, 40% have
asymptomatic PE [9]. However, while there is homology
within VTE, there are important epidemiological differ-
ences between DVT and PE. Mortality is higher for PE
than for DVT [3]. In the International Cooperative
Embolism Registry [10] set up to determine baseline
mortality rates and mechanisms of death, the 3-month
overall mortality rate was 15% and the factors that were
significantly associated with increased mortality were
systolic arterial hypotension, congestive heart failure,
cancer, tachypnoea, right ventricular hypokinesia, COPD,
and age >70 years. Resolution of PE is variable. It has
been reported that a majority of patients have unresolved
PE at 6 months from diagnosis [11]. Others have reported
rapid resolution of a large PE within hours of the onset of
heparin therapy [12]. Fredin and Arborelius noted com-
plete restoration of lung perfusion in patients with PE
within 1 week of diagnosis [13]. On the basis of this
rapidly changing pattern of perfusion in PE, Coakley
recommended that imaging tests for PE diagnosis should
be carried out as soon as possible, preferably within 24 h
after onset of symptoms [14].
Pathophysiology of PE
The pathophysiology of PE has been reviewed [15, 16].
Ventilation of unperfused regions will cause increased dead
space [17]. This is one reason for dyspnoea. Hypoxia, often
seen in major PE, is caused by several mechanisms. Emboli
occluding pulmonary end arteries may lead to haemorrhage,
pleuritic pain, pleural effusion and atelectasis. The lung has
no pain fibres. Pain with PE indicates involvement of
parietal pleura.
The haemodynamic effects of major PE on the circulation
have been recently reviewed [18]. Increased pulmonary
vascular resistance may lead to right ventricle strain and
failure, electromechanical dissociation, hypotension syncope
and sudden death. An increase in right atrial pressure can
lead to right to left shunt through a patent foramen ovale that
contributes to hypoxaemia. The shunt can also lead to
paradoxical emboli, implying that thrombus of venous origin
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causes infarctions in the major circulation, commonly the
brain [19].
Clinical presentation of PE
The clinical spectrum of PE in humans ranges from
asymptomatic to sudden death. Various studies have shown
that PE may be clinically silent [9]. The majority of patients
with PE present with recognized patterns of symptoms that
may include unexplained breathlessness, chest pain (central
or pleuritic), cough, haemoptysis, syncope, palpitations,
tachypnoea, tachycardia (heart rate >100 bpm), cyanosis,
fever, hypotension (systolic blood pressure <100 mmHg),
right heart failure, pulmonary hypertension and leg swell-
ing. However, these clinical features are also common in
patients who turn out not to have PE [20]. These clinical
features may develop abruptly or insidiously over days and
weeks. While certain symptoms and signs are more
commonly observed in PE than in other conditions, it is
not possible to confirm a diagnosis of PE on clinical
features alone. The diagnosis PE must be confirmed or
refuted on the basis of a conclusive imaging test.
Objectives
The primary objective of the Task Group was to develop
guidelines for the use of V/PSCAN for the diagnosis and
follow-up of PE. A further objective was to promote its
rational use in routine clinical practice using state of the art
methodology. In this first part of the Guidelines, the
principles and techniques for V/PSPECT are presented, as
well as its clinical utility for diagnosis of PE and additional
cardiopulmonary diagnoses.
Imaging tests for the diagnosis of PE
As detailed above, PE is a disease with a high mortality if
left untreated. Treatment is associated with significant risks.
The diagnosis cannot be established solely on the basis of
clinical observations or on the outcome of simple inves-
tigations such as ECG, chest plain radiography or blood
chemistry. It follows that imaging tests are required to
confirm or refute a diagnosis of PE. A number of imaging
tests have been employed for this purpose as follows:
1. Conventional PA, previously regarded as the gold
standard.
2. V/PSCAN was for a long time the principal diagnostic
method of choice. Occasionally, perfusion-only lung
scanning is performed.
3. MDCT angiography is now frequently cited as the
primary diagnostic method for the diagnosis of PE.
4. Magnetic resonance pulmonary angiography is still at
an early stage of development.
In a study by Baile et al. using a methacrylate cast of
the porcine pulmonary vessels as the independent
standard, PA had a sensitivity of only 87 % and a
positive predictive value of 88% [21]. They concluded
that the use of PA as the gold standard can be misleading.
Additionally, PA is invasive, difficult to perform and not
readily available. Interpretation is complicated by wide
interobserver variability [22, 23]. PA is now rarely used in
routine clinical practice. Still, in special cases, PA has a
role in centres with highly qualified angiographers.
Methods based upon magnetic resonance are not yet
established and are not discussed further.
V/PSCAN for the diagnosis of PE is universally available
but imaging protocols and interpretative strategies show
large variation. It is important to analyse such variations as
a basis for guidelines with the intention of standardizing
methods for imaging and interpretation throughout Europe.
Basic principles of PE diagnosis
V/PSCAN exploits the unique pulmonary arterial segmental
anatomy. Each bronchopulmonary segment is supplied by a
single end-artery (Fig. 1). In principle conical bronchopul-
monary segments have their apex towards the hilum and
base projecting onto the pleural surface. Occlusive thrombi
affecting individual pulmonary arteries therefore produce
characteristic lobar, segmental or subsegmental peripheral
wedge-shaped defects with the base projecting to the lung
periphery (Fig. 2).
V/P mismatch Within bronchopulmonary segment(s)
affected by PE, ventilation is usually preserved. This
pattern of preserved ventilation and absent perfusion
within a lung segment gives rise to the fundamental
rubric for PE diagnosis using V/PSCAN known as V/P
mismatch. At a later stage, when emboli become partly
resolved or recanalization occurs, the pattern of V/P
mismatch becomes less distinct. It is generally accepted
that a normal pulmonary perfusion pattern excludes PE
adequately [24–26]. PE are commonly multiple, most
likely because emboli fragment when passing through the
right heart and main pulmonary arteries. PE can be a
single event or a recurring process giving rise to multiple
emboli over short or long periods of time. It is important
to note that V/P mismatch is not caused exclusively by PE.
V/P mismatch involving pulmonary, lobar, segmental or
subsegmental arteries may be caused by other disorders
such as congenital pulmonary vascular abnormalities,
venoocclusive disease, vasculitis, lung cancer or tuberculous
mediastinal adenopathy [27, 28].
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V/P match It has long been recognized that the pulmonary
arterial circulation can be affected by intrinsic disorders of
the lung, other than PE. In these lung disorders, it is usually
the case that both ventilation and perfusion are affected.
Perfusion defects associated with ventilation defects are
usually caused by disorders of the airways or the lung
parenchyma. Such patterns are referred to as V/P match or
in cases where ventilation is more severely affected than
perfusion, reversed V/P mismatch.
The diagnosis of PE using V/PSCAN is therefore based
upon the finding of V/P mismatch. The ventilation scan
maps regional ventilation and helps define lung borders,
thereby facilitating the recognition of peripheral perfusion
defects. The ventilation scan may also provide additional
information about cardiopulmonary disorders other than
PE. For example, in COPD, the distribution of ventilation is
uneven and in aerosol studies focal deposition is often
observed in central or peripheral airways. Pneumonias
cause regional ventilation defects, usually more extensive
than the associated perfusion defects. Preserved perfusion
along the pleural border, recognized as the “stripe sign”
may be observed [29, 30].
A combined ventilation and perfusion study increases
the specificity for PE diagnosis and allows recognition of
alternative pathology. It is therefore recommended that in
PE diagnosis, a combined 1-day protocol is used. Other-
wise, up to 60% false-positive results may occur in elderly
patients, since obstructive airway disease increases signif-
icantly with age [31]. By contrast, ventilation scans are
often normal in young healthy individuals, for example in
pregnancy. To cut down on radiation exposure, a ventilation
scan can be avoided in the majority of patients in the first
trimester of pregnancy.
Ventilation scintigraphy
For mapping regional ventilation the following products are
used: inert gases 133Xe and 81mKr, and radiolabelled
aerosols 99mTc-DTPA and 99mTc-labelled Technegas.
Fig. 2 Sagittal slice of the left lung in a patient with PE. The
perfusion defect is wedge-shaped (arrow). Ventilation is preserved.
The abnormality is highlighted in the V/P quotient image (arrow)
Fig. 1 Segmental map of the
lungs as frontal slices from
anterior to posterior and sagittal
slices from right periphery to
left periphery
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133Xe
133Xe is historically the agent that was used for ventilation
studies [32, 33]. It has a half-life of 5 days and allows studies
of regional ventilation. In the PIOPED I study, the simple
single-breath technique was used in most cases [34]. 131Xe
was inhaled and during the first 20 s one image was obtained
from the posterior view. Due to the low energy of 131Xe (81
keV) insufficient information was obtained from anterior parts
of the lung. Frequently, perfusion defects caused by obstruc-
tion will be regarded as mismatch, leading to a false-positive
PE diagnosis [35]. The availability of 133Xe in Europe is
limited and it is hardly used for the diagnosis of PE.
81mKr
81mKr is a gas produced from a generator of rubidium (81Ru)
[36]. This gas has the ideal gamma energy of 193 keV and a
half-life of 13 s. The short half-life implies that inhaled
81mKr disappears from the alveolar space at a much faster
rate by decay than by exhalation. When a patient is breathing
air with 81mKr at a normal respiratory rate, the regional
alveolar 81mKr concentration is at steady state, closely
proportional to regional ventilation. Deviation from propor-
tionality occurs in lung compartments with very high or low
regional ventilation in relation to resident alveolar volume
[37]. This deviation occurs in young children with a high
ventilatory rate and a high ventilation/volume ratio [38].
During steady-state 81mKr ventilation, multiple planar imag-
ing or SPECT acquisition is feasible. Very recently, V/PSPECT
in combination with low-dose CT has been described [39].
81mKr is a true gas that does not cause artefacts due to
central airway deposition. An advantage is that ventilation and
perfusion can be imaged simultaneously as 81mKr has higher
gamma energy than 99mTc, which is used as a perfusion
marker (140 keV) [40–42]. As 81Ru has a half-life of 4.6 h,
the generator can be used for 1 day only. Limited access,
high cost and the need for a daily generator explains why
81mKr is not widely used. However, 81mKr remains a
valuable alternative to aerosols. Very low radiation exposure
makes 81mKr particularly suitable for use in children [38].
Aerosols
For ventilation scintigraphy, radioaerosols are usually used.
An aerosol is a relatively time-stable two-phase system
consisting of particles suspended in gas (air). The radio-
labelled particles may be liquid, solid or a combination of the
two. The percentage of particles remaining in the lung after
inhalation (deposition fraction), depends on the aerodynamic
properties of the particles, mainly their size. Deposition
fraction is up to 50% with ultrafine nanoparticles (diameter
0.02). These are deposited predominantly in the alveolar
region by diffusion [43]. The deposition fraction decreases to
25% with nanoparticles of diameter 0.1 µm [44]. The lowest
deposition fraction is found with particles of diameter
0.45 µm [43]. At this particle size, the aerosol is particularly
stable because diffusion and sedimentation as deposition
mechanisms balance each other. These fine particles are still
able to penetrate to the alveolar region [45].
Another deposition mechanism is impaction that occurs
with particles of diameter >1 µm in the lower respiratory tract.
Particles of diameter >5 µm impact in the upper airways. Even
small particles may impact with turbulent flow at stenoses.
This leads to hot spots, indicative of obstructive airway
disease. Breathing pattern is also of importance for aerosol
deposition [46]. At slow tidal breathing even relatively large
particles may reach the lung periphery [47].
The radioactivity carried by each liquid particle is
proportional to its volume, which increases with the cube
of the diameter. Doubling the diameter increases the
volume by a factor of eight. The deposition pattern depends
not only upon particle size but also on, for example, particle
shape. The composite property of a particle is therefore
expressed as its aerodynamic diameter. The two most
important characteristics of an aerosol are mass median
aerodynamic diameter (MMAD) and dispersion expressed
as its geometric standard deviation. MMAD should prefer-
ably be <1.2 µm [48–51]. A further complicating issue is
that liquid particles are hydrophilic and grow in size in the
humidity of airways.
Several nebulizers producing liquid aerosols are avail-
able on the market. The MMAD of the droplets should be
as low as possible. The maximum droplet size inhaled by
the patient should not exceed 2 µm. Because of the
complex physics behind aerosol deposition patterns, the
performance of a nebulizer must be clinically tested. Poor
performance is characterized by a high degree of deposition
in conducting airways. In patients with obstructive airway
disease, a predominant central deposition and hot spots may
severely hamper interpretation of ventilation scintigraphy.
Using the best available nebulizers this problem occurs in
rather few patients.
The most commonly used radiolabelled liquid aerosol is
99mTc-DTPA. 99mTc-DTPA is cleared from the alveolar
region by transepithelial diffusion [52]. The biological half-
life varies from 80±20min in healthy nonsmokers to 45±8 min
in healthy passive smokers and 24±9 min in healthy smokers
[53]. Resorbed 99mTc-DTPA is excreted via glomerular
filtration in the kidneys.
The pulmonary clearance rate of 99mTc-DTPA is an
index of the alveolar epithelial membrane integrity [53, 54].
Increased clearance, leads to a shorter half-life and occurs
with alveolar inflammatory activity of any kind such as
alveolitis of an allergic or toxic nature. For diagnostic use,
the clearance of 99mTc-DTPA can be evaluated using planar
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or tomographic scintigraphy [55, 56]. Continuous recording
over 20–45 min allows more detailed analysis for evaluation
of biphasic clearance in disease [57–59].
Technegas is an aerosol comprising extremely small
99mTc-labelled solid graphite particles generated at high
temperature [60, 61]. Technegas particles have a diameter
of about 0.005–0.2 µm [62] and are hydrophobic but tend
to grow by aggregation, and should therefore be used
within 10 min of generation. The graphite particles are
slowly cleared from the alveolar region by resorption. The
biological half-life is 135 h [63]. Ventilation studies with
99mTc-Technegas and with 81mKr give comparable infor-
mation [64–68]. However, hot spots are rarely seen with
99mTc-Technegas in patients with airway obstruction [66,
69]. Using 99mTc-Technegas has minimized the problem of
hotspots in patients with obstructive lung disease and is
according to clinical experience better than the best liquid
aerosols.
Perfusion scintigraphy
99mTc-MAA
Perfusion scintigraphy is accomplished by microemboliza-
tion with radiolabelled particles injected into a peripheral
vein. The commercially used particles are MAA which are
labelled with 99mTc. They are 15–100 µm in size and lodge
in the pulmonary capillaries and in the precapillary arterio-
les. The particle distribution accurately defines regional
lung perfusion. When performing the study, an important
factor is the number of particles injected. A minimum of
60,000 particles is required to obtain uniform distribution of
activity reflecting regional perfusion [70]. Normally, about
400,000 labelled particles are injected. Bearing in mind that
there are over 280 billion pulmonary capillaries and 300
million precapillary arterioles, the administration of up to
400,000 particles will result in obstruction of only a very
small fraction of pulmonary vessels. A reduction in the
number of particles administered to between 100,000 and
200,000 is recommended in patients with known pulmo-
nary hypertension, right to left heart shunt or after a single
lung transplantation. In infants and children the number of
particles may be further reduced in accordance with weight
[38].
Quality control and injection practice
Radiochemical purity should be determined as it may vary
widely. As particles tend to settle on standing, the vial
should be shaken gently before use. Withdrawal of blood
into the syringe should be avoided as this will cause
aggregation of MAA particles that may result in perfusion
artefacts. The suspension containing 99mTc-MAA should be
given by slow intravenous bolus injection over 30 s while
the patient breathes at normal tidal volumes. This will
ensure that the particles are infused over several respiratory
cycles facilitating uniform distribution within the pulmonary
circulation.
Radiation activity and radiation exposure
A key objective of imaging in PE is to minimize radiation
exposure without sacrificing image quality and diagnostic
accuracy. The amounts of radiation involved must be
considered together with imaging protocols. Table 1 gives
basic data of relevance.
The biological half-life of 99mTc-DTPA is 55–108 min
[51] and of 99mTc-Technegas is 135 h [63].
Pregnancy
Pregnancy, particularly during the first trimester, poses
unique circumstances in relation to radiation hazards [75].
In pregnant women, the interpretation of lung perfusion
scintigraphy is usually straightforward because of the low
frequency of comorbid pulmonary disorders [76]. There-
fore, to minimize radiation, a 1- to 2-day protocol is
suggested. Perfusion-only scans should be performed on
day 1, using a reduced dose of 99mTc-MAA. In most
patients PE can be excluded on the basis of a normal
perfusion pattern. When the perfusion pattern is abnormal
but not diagnostic of PE, subcutaneous low molecular
Table 1 Data on radiation exposure in adults
Reference Radiopharmaceutical Administered activity (MBq) Critical organ, dose (mGy/MBq) Effective dose (mSv/MBq)
[71] 99mTc-MAA 40–120 Lungs, 0.067 0.017
[72] 99mTc-DTPA 20–30 Bladder, 0.047 0.007
[73] Technegas 20–30 Lungs, 0.11 0.015
[74] 81mKr 40–400 Lungs, 0.0068 0.0007
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heparin can be given until a ventilation study is performed on
day 2, using an activity deposited in the lung of 20–30 MBq.
After the first trimester the standard 1-day protocol or the 1- to
2-day protocol can be used.
Imaging protocols
V/PPLANAR compared to V/PSPECT
V/PSCAN may be carried out using V/PPLANAR or V/PSPECT.
There are compelling reasons for the introduction of
V/PSPECT. An occlusive clot in a segmental artery causes
on average a perfusion defect large enough to be detected
on the basis of six to eight planar images, despite the low
resolution of V/PPLANAR and motion artefacts [77]. How-
ever, difficulties arise, mainly in medial segments which are
located adjacent to the mediastinum and are poorly
visualized on the outer contour of the lung. Detection of
ventilation and perfusion defects at the subsegmental level
is possible by planar imaging, but is considerably better by
SPECT (Fig. 3). In a pig model with artificial subsegmental
emboli, the sensitivity of V/PPLANAR was 67% and of
V/PSPECT was 93% [78]. In clinical studies, Bajc et al.
identified 53% more mismatched regions with SPECT [79].
In a study by Collart et al., V/PSPECT increased the
specificity for PE from 78% to 96% at similar sensitivities
[80]. Reinartz et al. found a sensitivity and specificity of
0.76 and 0.85, respectively, with V/PPLANAR compared to
0.97 and 0.91 with V/PSPECT [81].
Fig. 3 Planar (a) and SPECT
(b) studies in the same patient
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V/PSCAN: the value of ventilation scintigraphy
V/PSCAN should be performed using a 1-day protocol for
the following reasons. PE is an acute and life-threatening
disease that should be diagnosed and treated without delay.
To save time and resources, protocols for both V/PPLANAR
and V/PSPECT with very low isotope doses have been
designed to allow a complete study from referral to report
within 1 h [56, 79, 82]. The gamma camera and the staff are
then only engaged on one occasion and then for a short
time, which not infrequently is a logistical prerequisite for a
1-day protocol. Furthermore, after a ventilation scan with
very low activity, moderate activity yields optimal perfu-
sion image quality, which is a central issue. With the
recommended protocol, the total radiation dose is lower
than in many current protocols.
Outpatient therapy for PE has been shown to be safe
[83–85]. The advantages include among others saving in
cost. Full safe outpatient treatment calls for immediate
diagnosis that depends on a 1-day V/P protocol. A further
value of ventilation scintigraphy is that it allows a
delineation of the lung that is independent of the perfusion
pattern. Perfusion defects, particularly in the middle lobe
and the lingula, may be overlooked in the absence of
ventilation images [86].
Interpretation of V/PSPECT is facilitated by V/P quotient
images, the acquisition of which requires that the ventila-
tion study is immediately followed by the perfusion study
[55, 79]. In the presence of perfusion perturbations,
ventilation scintigraphy is a prerequisite for the diagnosis
of PE particularly when combined with other lung diseases
as well as to provide an explanation of the patient’s
symptoms.
V/PPLANAR acquisition
If V/PSPECT is not feasible, planar imaging is performed
with at least four views (anterior, posterior, left and right
posterior oblique). Preferably six to eight projections are
used. The recommended matrix size is 256×256, used
with a high-resolution, low-energy collimator; 500–
1,000 kcounts per view is recommended. For further details
see Tagil et al. [56].
Perfusion-only scintigraphy
Perfusion defects are caused by a variety of lung diseases
and are considered nonspecific. The sensitivity and speci-
ficity of the perfusion scan alone in the diagnosis or
exclusion of PE was reappraised by Miniati et al. in the
PISA-PED study [87]. In that study, 890 patients with
suspected PE were evaluated. Pulmonary angiography
(selective or superselective) was in most cases used as
reference. Perfusion scans were independently attributed to
one of four predetermined categories: (1) normal (no
perfusion defects); (2) near-normal (impressions caused by
enlarged heart, hila, or mediastinum seen in an otherwise
normal scan); (3) abnormal, suggestive of pulmonary
embolism (single or multiple wedge-shaped perfusion
defects); and (4) abnormal, not suggestive of pulmonary
embolism (single or multiple perfusion defects other than
wedge-shaped). The perfusion scan yielded a sensitivity of
86%, and a specificity of 93% in relation to angiography.
Recently, the PISA-PED criteria were used to rate 889
perfusion scans from the PIOPED II trial. Lung scans were
examined by two independent readers. The weighted
sensitivity of the perfusion scan was 82%, and the weighted
specificity 96% [88].
Perfusion-only scintigraphy is recommended during
pregnancy and in patients with suspected massive PE.
V/PSPECT acquisition
In order to minimize vertical ventilation and perfusion
gradients, inhalation of aerosols and intravenous injections
of MAA should be performed in the supine position.
During inhalation, activity over the lungs should be
monitored to ensure adequacy of pulmonary deposition.
For V/PSPECT, a large field-of-view dual or triple head
gamma camera is needed to limit acquisition time and the
risk of patient movement. In a systematic study, Palmer
et al. tested the relationships between activities, acquisition
times, collimators and matrices for optimal SPECT imaging
[55]. A 1 to 4 activity ratio between ventilation and
perfusion was found to be optimal. An ideal combination
was 25–30 MBq for ventilation studies and 100–120 MBq
for perfusion studies. Images should be acquired using a
64×64 matrix and a general purpose collimator and a total
acquisition time of 20 min. In clinical practice this strategy
has proved to be feasible and adequate in several recent
studies [79, 89–92].
Many centres are using much higher doses. To reduce
radiation exposure to the lowest level possible with
maintained diagnostic safety is, on the basis of ethical
concerns and good medical practice, a crucial issue.
Therefore, the activities and acquisition protocol of Palmer
et al. are recommended [55].
The total number of projections is 128 (64 with each
camera head). For ventilation SPECT study each projection
takes 10 s. The perfusion study is undertaken immediately
after the ventilation SPECT acquisition without patient
movement, each projection lasting 5 s. During the examina-
tion the patient remains in the supine position, carefully
maintained between ventilation and perfusion acquisitions.
The total immobilization time of 20 min is well tolerated even
by critically ill patients. The procedure is practical for the staff.
Eur J Nucl Med Mol Imaging (2009) 36:1356–1370 1363
V/PSPECT reconstruction and display
Iterative reconstruction using OSEM (ordered-subset expec-
tation maximization) with, for example, eight subsets and two
iterations is recommended [55, 79, 93]. Standard software
can be used for this as well as for image presentation in the
frontal, sagittal and transverse projections as well as for
presentation of rotating 3-D images.
A further option is to calculate and display V/P quotient
images. Based upon acquisition in which the patient is
examined without movement between ventilation and perfu-
sion imaging, ventilation background may be subtracted from
perfusion tomograms [55, 79]. After normalization of the
ventilation to perfusion count rates, a ventilation/perfusion
quotient is calculated (V/Pquotient). The V/Pquotient images
facilitate diagnosis and quantification of PE extension,
particularly in complex cases. Notably, as attenuation is
similar for ventilation and perfusion studies, V/Pquotient
images make attenuation correction less important.
Interpretation of V/PSCAN
Diagnosis of acute PE
Probabilistic interpretation based upon simplistic criteria
were promoted through the PIOPED I study [34]. The terms
used were high, intermediate, low and very low probability
V/PSCAN, and indeterminate (nondiagnostic) examinations.
Such or similar terminology is extremely rare in other
clinical contexts. This language has not gained acceptance
in other fields. The most likely reason is that in clinical
practice this strategy is inherently impracticable. According
to Bayes’ theorem, probability cannot be defined from a
single test without taking into account prior probability.
Furthermore, the PIOPED I criteria were formulated and
applied on the basis of techniques that are today obsolete.
For example, regional ventilation was mapped from a
posterior planar acquisition following the inhalation of
133Xe. Additionally, an abnormal chest radiograph or
ventilation scintigram implied that the scintigraphy was
categorized as nondiagnostic, which is unwarranted as
shown by more recent studies [82, 90, 93]. In the PIOPED
study, direct comparison of conventional PA and planar
ventilation scintigraphy, using 133Xe for ventilation, yielded
poor results with agreement as low as 50% [34]. Therefore
the PIOPED criteria were fundamentally flawed.
Interpretation of imaging tests such as V/PSPECT and V/
PPLANAR should be based upon:
& Basic criteria for reading the images
& Knowledge and experience of the interpreter according
to the principle of “gestalt” [94, 95]
& Pretest probability in accordance with the principle of
Holistic interpretation
Furthermore, to be clinically useful, interpretation of an
imaging test should be affirmative or negative with respect
to PE (PE: yes or no) and should not be based on
probability categories [77].
The recommended basic criteria for reading V/PSPECT
and V/PPLANAR are the following:
No PE is reported if there is (are):
& Normal perfusion pattern conforming to the anatomic
boundaries of the lungs
& Matched or reversed mismatch V/P defects of any size,
shape or number in the absence of mismatch
& Mismatch that does not have a lobar, segmental or
subsegmental pattern
PE is reported if there is:
& V/P mismatch of at least one segment or two
subsegments that conforms to the pulmonary vascular
anatomy
Nondiagnostic for PE is reported if there are:
& Multiple V/P abnormalities not typical of specific
diseases.
The fundamental assumption behind these criteria is the
fact that in those patients with a clinical suspicion of PE, PE
is the principal cause of lobar, segmental or subsegmental V/
P mismatch. Howarth et al. stated that for diagnosis of PE
“more than 0.5 segment of ventilation/perfusion mismatch is
sufficient” [96]. Crucially, the shape of a mismatch should be
pleural based and should conform to known subsegmental
and segmental vascular anatomy as stressed in the PISA-
PED study [87]. Applying these principles of interpretation,
recent V/PSPECT studies amounting to over 3,000 cases have
shown negative predictive values of 97–99%, sensitivities of
96–99%, and specificities of 91–98% for PE diagnosis. Rates
of nondiagnostic findings were 1–3% [81, 82, 90, 93]. The
experience of the interpreter is involved in the process that
carries the name gestalt [94, 95]. Another term frequently
used is holistic interpretation, which implies that clinical
information and laboratory tests are taken into account
together with all observed signs and patterns in ventilation
and perfusion scintigrams. Schemes for clinical probabilities
may be of significant value [97–99]. This is further under-
lined in Part 2 of these guidelines [100].
Chronic PE
Chronic PE is a distinct entity. Its clinical presentation is often
insidious. It is progressive and without treatment has a poor
prognosis [101, 102]. Mortality is related to pulmonary
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hypertension, right heart failure and arrhythmia. V/PSCAN is
conventionally a mainstay in the diagnosis of chronic
thromboembolic pulmonary hypertension [103–105].
Recently, a group from Hammersmith Hospital reported a
head to head comparison between MDCT and V/PPLANAR in
patients with pulmonary hypertension. MDCT had a sensi-
tivity of 51% while the sensitivity of V/PPLANAR was
96–97% at a specificity of 90%, confirming previous data
[106]. The authors concluded that “ventilation/perfusion
scintigraphy, which is widely available and easy to perform,
has a higher sensitivity than MDCT as well as very good
specificity in detecting chronic pulmonary thromboembolic
disease as a potential curable cause of PH”. Figure 4
illustrates typical V/PSPECT findings in patients with
pulmonary hypertension caused by chronic PE, not
recognized by MDCT.
Additional diagnostic outcomes
In addition to the diagnosis of PE, V/PSCAN may provide
evidence of other pathologies, such as COPD, left heart
failure and pneumonia. The frequency of additional find-
ings using V/PSPECT has been reported to be 39% among
patients without PE, and 22% among patients with PE [90].
COPD is characterized on V/PSCAN by matched ventilation
and perfusion defects. Frequently, ventilation defects are
more pronounced than perfusion defects. This is known as
reverse mismatch [107, 108]. A significant correlation
between the degree of abnormalities on aerosol ventilation
imaging and pulmonary function tests has been reported
[109]. PE is quite frequent in COPD [110, 111] and
accounts for up to 10% of deaths in patients with stable
COPD [112]. PE can be diagnosed using V/PSPECT in
patients with coexisting COPD (Fig. 5).
In left heart failure, perfusion is redistributed towards
upper lung regions (Fig. 6) [92, 113, 114]. In a recent study
based on V/PSPECT in consecutive patients with suspected
PE, 99mTc-MAA was injected with the patient in the supine
position. Redistribution of perfusion towards ventral lung
regions was observed in 15% of the patients, indicating left
heart failure [92]. The positive predictive value for heart
failure was 88% or higher. In heart failure, ventilation is
usually redistributed to a lesser extent than perfusion, V/P
mismatch may be observed in dorsal regions. This V/P
mismatch has a nonsegmental diffuse pattern and should
not be misinterpreted as PE.
Fig. 4 Sagittal slices of the right lung in a patient with pulmonary
hypertension. Multiple perfusion defects are seen in ventilated areas,
highlighted in the V/P quotient images. MDCT was normal in this
patient
Fig. 5 Frontal slices in a patient with COPD and PE. Ventilation is
very uneven in the whole lung. In addition, multiple perfusion defects
are seen in ventilated areas. Mismatch is highlighted in V/Pquotient
images
Fig. 6 Sagittal slices from the right lung. Antigravitational redistribution
of perfusion is pronounced. Ventilation is less affected causing mismatch.
Note that the pattern is not of a segmental character
Eur J Nucl Med Mol Imaging (2009) 36:1356–1370 1365
Pneumonia is characterized by a matched ventilation/
perfusion pattern [115]. Ventilation defects usually exceed
perfusion defects, causing reverse mismatch [115, 116]. A
valuable sign of pneumonia is the ‘stripe sign’ that refers to
maintained perfusion along the pleural surface, peripheral
to a central matched defect (Fig. 7) [29, 30]. V/PSPECT
facilitates the identification of the stripe sign [89, 117].
Pitfalls in the interpretation of V/PSCAN
As with any diagnostic test, it is vital that the clinician
reporting the lung scan is aware of a number of sources of
error. These include the following:
& Technical artefacts may arise from preinjection handling
of the 99mTc-MAA. Drawing blood into the syringe
containing the solution of 99mTc -MAA may cause
aggregation of particles, creating hot spots in the
images. A similar result may arise from failure to
resuspend 99mTc-MAA particles prior to administration.
& Planar imaging may underestimate the presence or
extent of perfusion abnormalities due to superposition
of lung regions with normal perfusion. This is reflected
as shine-through masking of embolized regions. This
problem is eliminated by V/PSPECT (Fig. 3).
& Technegas is preferred over liquid aerosols in patients with
COPD. In rare patients with emphysema, Technegas
particles are trapped in bullae causing a pattern that may
be mistaken for a mismatch [81].
& Mismatched perfusion defects, which do not have a
clear segmental character, may be seen in older, partly
resolved PE, but are not the result of acute PE.
Moreover, nonsegmental mismatched defects are ob-
served in a number of lung disorders including lung
cancer, mediastinal lymphadenopathy, postradiation
pneumonitis/fibrosis and heart failure. V/PSPECT facili-
tates the identification of segmental perfusion defects,
which are particularly well visualized using rotating 3-D
volume images.
& It has been argued that V/PSCAN may fail to detect PE
when the thromboembolism causes only partial vascular
occlusion with few haemodynamic effects [118]. How-
ever, it is generally accepted that a negative V/PSPECT
scan excludes PE. Accordingly, this potential problem
has low clinical significance. An explanation for this
may be that nonocclusive emboli are paralleled by
occlusive PE in other regions leading to diagnosis. On
the other hand, if a partly occluding embolus is
recognized (segmental perfusion clearly reduced but
not absent while ventilation is normal), the finding
should be reported as PE.
& Unilateral absence of perfusion in a whole lung with
preserved ventilation and without any V/P mismatch in
the other lung is generally not due to PE [94, 119]. In
such cases, a CT scan of the thorax may reveal the
presence of other pathologies such as tumour and other
mediastinal processes, congenital pulmonary vascular
abnormalities or aortic aneurysm.
Conclusion
V/PSPECT is strongly recommended as it allows the
diagnosis of PE to be made with accuracy even in the
presence of diseases such as COPD and pneumonia.
Technegas is preferred over DTPA in patients with COPD.
When available, 81mKr is advantageous. The radiation
dose should be reduced as much as possible without
clinically significant image deterioration. This implies
30 MBq of 99mTc-aerosol for the ventilation scan preced-
ing 100–120 mBq for the perfusion scan both for V/
PPLANAR and V/PSPECT. In pregnancy only a perfusion
scan is recommended. Probabilistic interpretation is
obsolete and should be replaced by holistic interpretation.
A fundamental criterion for PE is mismatch in more than
one subsegment.
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Fig. 7 Sagittal slices of the left lung in a patient with extensive
pneumonia in whom the chest radiograph was interpreted as
atelectasis. The left lung shows nearly absent ventilation in areas with
much better perfusion (arrow stripe sign). V/P quotient highlights
reversed mismatch
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